RMTG Subsidiary Cellgenic to Host Soft Opening of Advanced Cell Therapy Manufacturing Lab in Cancun During September ISSCA Global Summit

About this update from Regenerative Medical Technology Group Inc.

[{"type":"text","content":"\r\n\r\n \r\n \r\n RMTG Subsidiary Cellgenic to Host Soft Opening of Advanced Cell Therapy Manufacturing Lab in Cancun During September ISSCA Global Summit\r\n \r\n \r\n\r\n\r\nRMTG Subsidiary Cellgenic to Host Soft Opening of Advanced Cell Therapy Manufacturing Lab in Cancun During September ISSCA Global Summit\r\n\r\n\r\n\r\n\r\n\r\nRMTG Subsidiary Cellgenic to Host Soft Opening of Advanced Cell Therapy Manufacturing Lab in Cancun During September ISSCA Global Summit\r\n COFEPRIS-Licensed Facility Positions Company for Full-Scale Operations by January 2026 LAS VEGAS, NV / ACCESS Newswire / August 25, 2025 / Regenerative Medical Technologies Group, Inc. (OTC:RMTG), a global leader in regenerative medicine solutions, today announced that its subsidiary Cellgenic will host the soft opening of its advanced cell therapy manufacturing facility in Cancun, Mexico during September 2025. The opening will coincide with the 2025 ISSCA Regenerative Medicine Global Summit, organized by the International Society for Stem Cell Application (ISSCA), RMTG's educational and scientific division through its Global Stem Cells Group subsidiary.\r\n Strategic Manufacturing Infrastructure:\r\n The soft opening represents a significant milestone in RMTG's international expansion strategy, with plans to establish specialized infrastructure designed for the controlled manufacture, preservation, and distribution of human cellular products. The strategically located Cancun facility will support production of investigational and regulated cell-based therapies, including mesenchymal stem cells (MSCs), exosomes, natural killer (NK) cells, and other biologics for orthopedics, neurology, pain management, aesthetic medicine, and longevity-focused therapies.\r\n Regulatory Compliance and Market Positioning:\r\n • COFEPRIS Authorization: Laboratory fully licensed by Mexico's federal health authority to operate as both a Stem Cell Collection Center and Stem Cell Bank\r\n • International Standards: ISO-classified cleanrooms, cryopreservation systems, GMP-aligned workflows, and digital batch traceability systems\r\n • Revenue Generation: Full-scale operations expected by January 2026, adding manufacturing revenue streams to RMTG's existing affiliate network spanning 30+ countries\r\n • Training Integration: Designated areas for physician ed...

More updates from Regenerative Medical Technology Group Inc.